Tags Archive Navigation
icon
-
Media ReleaseNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
-
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Media ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
Media ReleaseNovartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
-
Media ReleaseNovartis reaches milestone delivery of 1 billion courses of antimalarial treatment
-
Media ReleaseInternational research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa